Activation of the FGF2-FGFR1 autocrine pathway: A novel mechanism of acquired resistance to gefitinib in NSCLC

Hideki Terai, Kenzo Soejima, Hiroyuki Yasuda, Sohei Nakayama, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Shinnosuke Ikemura, Takashi Sato, Satoshi Yoda, Ryosuke Satomi, Katsuhiko Naoki, Tomoko Betsuyaku

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Patients with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutations initially respond to EGFR-tyrosine kinase inhibitors (TKI) but eventually experience relapse. Acquired resistance to EGFR-TKIs is strongly associated with patient mortality. Thus, elucidation of the mechanism of acquired resistance to EGFR-TKIs is of great importance. In this study, gefitinib-resistant cell line models were established by long-term exposure to gefitinib using the gefitinib-sensitive lung cancer cell lines, PC9 and HCC827. Expression analyses indicated that both FGFR1 and FGF2 were increased in PC9 gefitinib-resistant (PC9 GR) cells as compared with PC9 naïve (PC9 na) cells. Importantly, proliferation of gefitinib-resistant cells was dependent on the FGF2-FGFR1 pathway. Mechanistically, inhibition of either FGF2 or FGFR1 by siRNA or FGFR inhibitor (PD173074) restored gefitinib sensitivity in PC9 GR cells. These data suggest that FGF2-FGFR1 activation through an autocrine loop is a novel mechanism of acquired resistance to EGFR-TKIs.

Original languageEnglish
Pages (from-to)759-767
Number of pages9
JournalMolecular Cancer Research
Volume11
Issue number7
DOIs
Publication statusPublished - 2013 Jul

Fingerprint

Fibroblast Growth Factor 2
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Cell Line
gefitinib
Protein-Tyrosine Kinases
Small Interfering RNA
Lung Neoplasms
Recurrence
Mutation
Mortality

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology

Cite this

Activation of the FGF2-FGFR1 autocrine pathway : A novel mechanism of acquired resistance to gefitinib in NSCLC. / Terai, Hideki; Soejima, Kenzo; Yasuda, Hiroyuki; Nakayama, Sohei; Hamamoto, Junko; Arai, Daisuke; Ishioka, Kota; Ohgino, Keiko; Ikemura, Shinnosuke; Sato, Takashi; Yoda, Satoshi; Satomi, Ryosuke; Naoki, Katsuhiko; Betsuyaku, Tomoko.

In: Molecular Cancer Research, Vol. 11, No. 7, 07.2013, p. 759-767.

Research output: Contribution to journalArticle

Terai, H, Soejima, K, Yasuda, H, Nakayama, S, Hamamoto, J, Arai, D, Ishioka, K, Ohgino, K, Ikemura, S, Sato, T, Yoda, S, Satomi, R, Naoki, K & Betsuyaku, T 2013, 'Activation of the FGF2-FGFR1 autocrine pathway: A novel mechanism of acquired resistance to gefitinib in NSCLC', Molecular Cancer Research, vol. 11, no. 7, pp. 759-767. https://doi.org/10.1158/1541-7786.MCR-12-0652
Terai, Hideki ; Soejima, Kenzo ; Yasuda, Hiroyuki ; Nakayama, Sohei ; Hamamoto, Junko ; Arai, Daisuke ; Ishioka, Kota ; Ohgino, Keiko ; Ikemura, Shinnosuke ; Sato, Takashi ; Yoda, Satoshi ; Satomi, Ryosuke ; Naoki, Katsuhiko ; Betsuyaku, Tomoko. / Activation of the FGF2-FGFR1 autocrine pathway : A novel mechanism of acquired resistance to gefitinib in NSCLC. In: Molecular Cancer Research. 2013 ; Vol. 11, No. 7. pp. 759-767.
@article{abc1d399fc6c40d59f7e81267dfb9c9b,
title = "Activation of the FGF2-FGFR1 autocrine pathway: A novel mechanism of acquired resistance to gefitinib in NSCLC",
abstract = "Patients with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutations initially respond to EGFR-tyrosine kinase inhibitors (TKI) but eventually experience relapse. Acquired resistance to EGFR-TKIs is strongly associated with patient mortality. Thus, elucidation of the mechanism of acquired resistance to EGFR-TKIs is of great importance. In this study, gefitinib-resistant cell line models were established by long-term exposure to gefitinib using the gefitinib-sensitive lung cancer cell lines, PC9 and HCC827. Expression analyses indicated that both FGFR1 and FGF2 were increased in PC9 gefitinib-resistant (PC9 GR) cells as compared with PC9 na{\"i}ve (PC9 na) cells. Importantly, proliferation of gefitinib-resistant cells was dependent on the FGF2-FGFR1 pathway. Mechanistically, inhibition of either FGF2 or FGFR1 by siRNA or FGFR inhibitor (PD173074) restored gefitinib sensitivity in PC9 GR cells. These data suggest that FGF2-FGFR1 activation through an autocrine loop is a novel mechanism of acquired resistance to EGFR-TKIs.",
author = "Hideki Terai and Kenzo Soejima and Hiroyuki Yasuda and Sohei Nakayama and Junko Hamamoto and Daisuke Arai and Kota Ishioka and Keiko Ohgino and Shinnosuke Ikemura and Takashi Sato and Satoshi Yoda and Ryosuke Satomi and Katsuhiko Naoki and Tomoko Betsuyaku",
year = "2013",
month = "7",
doi = "10.1158/1541-7786.MCR-12-0652",
language = "English",
volume = "11",
pages = "759--767",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Activation of the FGF2-FGFR1 autocrine pathway

T2 - A novel mechanism of acquired resistance to gefitinib in NSCLC

AU - Terai, Hideki

AU - Soejima, Kenzo

AU - Yasuda, Hiroyuki

AU - Nakayama, Sohei

AU - Hamamoto, Junko

AU - Arai, Daisuke

AU - Ishioka, Kota

AU - Ohgino, Keiko

AU - Ikemura, Shinnosuke

AU - Sato, Takashi

AU - Yoda, Satoshi

AU - Satomi, Ryosuke

AU - Naoki, Katsuhiko

AU - Betsuyaku, Tomoko

PY - 2013/7

Y1 - 2013/7

N2 - Patients with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutations initially respond to EGFR-tyrosine kinase inhibitors (TKI) but eventually experience relapse. Acquired resistance to EGFR-TKIs is strongly associated with patient mortality. Thus, elucidation of the mechanism of acquired resistance to EGFR-TKIs is of great importance. In this study, gefitinib-resistant cell line models were established by long-term exposure to gefitinib using the gefitinib-sensitive lung cancer cell lines, PC9 and HCC827. Expression analyses indicated that both FGFR1 and FGF2 were increased in PC9 gefitinib-resistant (PC9 GR) cells as compared with PC9 naïve (PC9 na) cells. Importantly, proliferation of gefitinib-resistant cells was dependent on the FGF2-FGFR1 pathway. Mechanistically, inhibition of either FGF2 or FGFR1 by siRNA or FGFR inhibitor (PD173074) restored gefitinib sensitivity in PC9 GR cells. These data suggest that FGF2-FGFR1 activation through an autocrine loop is a novel mechanism of acquired resistance to EGFR-TKIs.

AB - Patients with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutations initially respond to EGFR-tyrosine kinase inhibitors (TKI) but eventually experience relapse. Acquired resistance to EGFR-TKIs is strongly associated with patient mortality. Thus, elucidation of the mechanism of acquired resistance to EGFR-TKIs is of great importance. In this study, gefitinib-resistant cell line models were established by long-term exposure to gefitinib using the gefitinib-sensitive lung cancer cell lines, PC9 and HCC827. Expression analyses indicated that both FGFR1 and FGF2 were increased in PC9 gefitinib-resistant (PC9 GR) cells as compared with PC9 naïve (PC9 na) cells. Importantly, proliferation of gefitinib-resistant cells was dependent on the FGF2-FGFR1 pathway. Mechanistically, inhibition of either FGF2 or FGFR1 by siRNA or FGFR inhibitor (PD173074) restored gefitinib sensitivity in PC9 GR cells. These data suggest that FGF2-FGFR1 activation through an autocrine loop is a novel mechanism of acquired resistance to EGFR-TKIs.

UR - http://www.scopus.com/inward/record.url?scp=84880547779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880547779&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-12-0652

DO - 10.1158/1541-7786.MCR-12-0652

M3 - Article

C2 - 23536707

AN - SCOPUS:84880547779

VL - 11

SP - 759

EP - 767

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 7

ER -